Barnali Paul, PhD
Staff Scientist
Dr. Barnali Paul is a staff scientist in the Majumdar Lab. Dr. Paul is originally from West Bengal, the eastern part of India. She earned her master’s degree in chemistry at University of North Bengal, Siliguri, West Bengal in India. She pursued doctoral training in medicinal chemistry at the Indian Institute of Chemical Biology, Kolkata, under supervision of Dr. Arindam Talukdar. During her PhD studies, she focused on the design and development of novel immunomodulators targeting Toll-like receptors and Piezo-type mechanosensitive ion channels. Following her doctoral work, she moved to the United States to continue advancing her research interests in medicinal chemistry. She joined the Center for Clinical Pharmacology, where she has focused on mu opioid receptors, which are part of the G-protein-coupled receptor family.
Her research is centered on the design and development of novel compounds that target opioid receptors, using a structure-guided medicinal chemistry approach to optimize both efficacy and safety profiles. Conventional opioids such as morphine and fentanyl are among the most effective pain relievers available, but their clinical use is severely limited by serious and life-threatening side effects, including respiratory depression, dependence, and addiction. Her goal is to identify and refine chemical structures that preserve analgesic activity while reducing harmful adverse effects. To achieve this, she focused her work on mitragynine pseudoindoxyl, a metabolite derived from the natural product kratom, as a scaffold for modulating efficacy at the μ-opioid receptor. Through diversification of mitragynine pseudoindoxyl and pharmacological characterization of the resulting compounds, she developed candidates that act as therapeutics for both pain and opioid
withdrawal syndrome.
In her free time, Dr. Paul enjoys reading, spending time with her family, traveling, hiking, and experimenting with a variety of international cuisines.